SCHEMBL321083

SCHEMBL321083

CCCCOC(=O)CCCBr

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.63
ALDH1A1 P00352 1/20 0.52
NAAA Q02083 1/20 0.52
FAAH O00519 1/20 0.52
DNM1 Q05193 1/20 0.52
HTR2C P28335 1/20 0.50
PRSS1 P07477 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49
ATM Q13315 1/20 0.48
PAM P19021 2/20 0.47
EPHX2 P34913 4/20 0.46
TSHR P16473 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
RECQL P46063 1/20 0.45
HPGD P15428 1/20 0.45
MGLL Q99685 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365023 0.94 DGKA (0.67) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL19032628 0.94 DGKA (0.67) DGKANAAAFAAHDNM1HTR2C
SCHEMBL1366455 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL6120282 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL1364973 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL25343011 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL22092052 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL1366913 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL11639639 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1
SCHEMBL21811479 0.92 DGKA (0.70) DGKAALDH1A1NAAAFAAHDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113980117-B Fenpyroximate antigen and preparation method and application thereof 西南大学 2024-07-12 CN claimed
CN-117820460-A Methoxypiperidine ethyl antigen and preparation method and application thereof 西南大学 2024-04-05 CN claimed
CN-114560834-B Spirodiclofen hapten, antigen and antibody as well as preparation methods and applications thereof 西南大学 2024-02-09 CN claimed
CN-114560834-A Spirodiclofen hapten, antigen and antibody as well as preparation method and application thereof 西南大学 2022-05-31 CN claimed
CN-113980117-A Fenpyroximate antigen and preparation method and application thereof 西南大学 2022-01-28 CN claimed
WO-2025126793-A1 METHOD FOR PRODUCING POLYCARBOXYLIC ACID ESTER COMPOUND 本州化学工業株式会社 2025-06-19 WO disclosed
WO-2025126794-A1 METHOD FOR PRODUCING POLYCARBOXYLIC ACID ESTER COMPOUND 本州化学工業株式会社 2025-06-19 WO disclosed
WO-2025106386-A1 A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-22 WO disclosed
CN-113980117-B Fenpyroximate antigen and preparation method and application thereof 西南大学 2024-07-12 CN disclosed
US-12030834-B2 Methods of synthesizing 4-valyloxybutyric acid XWPharma Ltd. (KY) 2024-07-09 US disclosed
US-11958802-B2 Migration-resistant photopolymerization sensitizer KAWASAKI KASEI CHEMICALS LTD. (JP) 2024-04-16 US disclosed
CN-117820460-A Methoxypiperidine ethyl antigen and preparation method and application thereof 西南大学 2024-04-05 CN disclosed
WO-2005121904-A1 CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS CANON KABUSHIKI KAISHA (JP) 2005-12-22 WO disclosed
WO-2005121204-A2 POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR CANON KABUSHIKI KAISHA (JP) 2005-12-22 WO disclosed
EP-0777656-B1 NOVEL DNA-TARGETED ALKYLATING AGENTS AUCKLAND DIVISION CANCER SOC O (NZ) 2004-04-14 EP disclosed
US-5968933-A ANTITUMOR AGENTS AND BINDING DNA FOR MUTAGENESIS AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) 1999-10-19 US disclosed
EP-0777656-A4 NOVEL DNA-TARGETED ALKYLATING AGENTS CANCER SOC AUCKLAND DIV NZ INC (NZ) 1998-04-15 EP disclosed
EP-0777656-A1 NOVEL DNA-TARGETED ALKYLATING AGENTS AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND (INCORPORATED) (NZ) 1997-06-11 EP disclosed
WO-1996006831-A1 NOVEL DNA-TARGETED ALKYLATING AGENTS AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) 1996-03-07 WO disclosed
EP-0137426-A2 2-Mercaptothiazole derivatives, process for their preparation and utilization of 2-mercaptothiazole derivatives in pharmaceutical compounds BAYER AG (DE) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030834-B2 Methods of synthesizing 4-valyloxybutyric acid GABBR1, GABBR2, GABRB3 DGKA 979/4885ALDH1A1 2199/4885NAAA 326/4885
US-11958802-B2 Migration-resistant photopolymerization sensitizer F12, F10, PCNA DGKA 2032/4885ALDH1A1 838/4885NAAA 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.